Recent Updates
Recently added Catalysts

Psychosis in Alzheimer's Disease: one US-listed biotech with a clinical-stage programme

Neurology & PsychiatryUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$560Muniverse median $1.20B
Allocated capital$187M$560M competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank256/299crowding rank 258

Psychosis in Alzheimer's Disease is uncontested. MapLight Therapeutics (MPLT) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with ML-007C-MA in phase 2.

There is no public comparable to price it against. MPLT spreads its $560M market cap across 3 indications, so $187M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$187M of allocated capital sits in Psychosis in Alzheimer's Disease, ranking it 256th of 299 indications by the money committed to it.

Companies developing drugs for Psychosis in Alzheimer's Disease 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
MPLTMapLight TherapeuticsML-007C-MAPhase 22$560MNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Psychosis in Alzheimer's Disease counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Psychosis in Alzheimer's Disease has one competitor and a median of $560M.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

Migraine1 company · $218M · median $436MUncontestedOsteoarthritis Knee Pain1 company · $265M · median $1.1BUncontestedAcute Postoperative Pain1 company · $265M · median $1.1BUncontestedPostoperative Pain1 company · $265M · median $1.1BUncontestedCervical Spinal Cord Injury1 company · $278M · median $278MUncontestedRelapsing Remitting Multiple Sclerosis1 company · $87M · median $174MUncontestedCharcot-Marie-Tooth Disease1 company · $46M · median $323MUncontestedPrimary Insomnia1 company · $46M · median $323MUncontested

Psychosis in Alzheimer's Disease pipeline questions

Which biotech companies are developing drugs for Psychosis in Alzheimer's Disease?

MapLight Therapeutics (MPLT, ML-007C-MA, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Psychosis in Alzheimer's Disease.

How advanced is the Psychosis in Alzheimer's Disease pipeline?

Of the 1 clinical-stage programme in Psychosis in Alzheimer's Disease, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Psychosis in Alzheimer's Disease?

No. MPLT is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Psychosis in Alzheimer's Disease, which is why the indication is classified as uncontested.

When is the next Psychosis in Alzheimer's Disease catalyst?

The next dated catalyst in Psychosis in Alzheimer's Disease is MPLT on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map